Defence Therapeutics Inc.

BRIEF

published on 05/02/2024 at 08:05, 6 months 19 days ago

Successful Pre-clinical Trial for Defence Therapeutics' ARM-002 Anti-Cancer Vaccine

Defence Therapeutics Immune Therapy ARM-002 Vaccine Pancreatic Cancer Pre-clinical Trials
PRESS RELEASE

published on 05/02/2024 at 08:00, 6 months 19 days ago

PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
Defence Therapeutics Inc. successfully completes pre-clinical trial using its ARM-002 anti-cancer vaccine against pancreatic cancer, showing therapeutic effectiveness and potential benefits

Defence Therapeutics Inc. Vaccine Pancreatic Cancer ARM-002 Pre-clinical Trial
BRIEF

published on 04/23/2024 at 08:05, 6 months 28 days ago

Defence’s ARM-002 Shows Promise in Advanced Melanoma Treatment

Melanoma Treatment Defence Therapeutics AccuTOX Technology Immune-oncology ARM-002 Vaccine
PRESS RELEASE

published on 04/23/2024 at 08:00, 6 months 28 days ago

DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION
Defence Therapeutics Inc. announces the potent antigen presentation of its ARM-002 anti-cancer vaccine using AccuTOX technology, showing therapeutic effectiveness against melanoma

Immunotherapy Defence Therapeutics Inc. AccuTOX Technology Melanoma ARM-002 Anti-cancer Vaccine
BRIEF

published on 04/17/2024 at 08:05, 7 months 4 days ago

Defence Therapeutics Partners with FMS Consult GmbH to Enhance Financial Strategy

Cancer Treatment Biopharmaceuticals Financial Strategy Defence Therapeutics FMS Consult GmbH
PRESS RELEASE

published on 04/17/2024 at 08:00, 7 months 4 days ago

DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
Defence Therapeutics Inc. partners with FMS Consult GmbH for financing strategy to support pipeline growth. The company aims to advance growth in developing immune-oncology therapeutics and drug delivery technologies

Defence Therapeutics Inc. FMS Consult GmbH Financing Strategy Immune-oncology Therapeutics Clinical Stage Oncology Company
BRIEF

published on 03/26/2024 at 13:35, 7 months 26 days ago

Defence Therapeutics Announces Development of Second-Generation Cancer Vaccine ARM-002(TM)

Immunotherapy Defence Therapeutics AccuTOX® Cancer Vaccine ARM-002(TM)
PRESS RELEASE

published on 03/26/2024 at 13:30, 7 months 26 days ago

ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
Defence Therapeutics Inc. announces successful testing of second-generation cancer vaccine ARM-002TM, utilizing AccuTOX® molecule for tumor eradication. Promising results in melanoma model point to potential breakthrough in cancer treatment

Defence Therapeutics Inc. ARM-002TM Melanoma Cancer Vaccine AccuTOX® Molecule
BRIEF

published on 03/26/2024 at 08:05, 7 months 26 days ago

Defence Therapeutics Announces Advancement in Anti-Cancer Vaccine with ARM-002TM

Defence Therapeutics AccuTOX® Anti-cancer Vaccine Immune-oncology ARM-002TM
PRESS RELEASE

published on 03/26/2024 at 08:00, 7 months 26 days ago

DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
Defence Therapeutics announces successful results for second-generation anti-cancer vaccine ARM-002TM, showing promising anti-tumoral response in melanoma model and plans for Phase I trial targeting solid tumors

Phase I Trial Defence Therapeutics Anti-cancer Vaccine ARM-002TM Melanoma

Published on 11/21/2024 at 17:35, 20 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 25 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 25 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 54 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 55 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 1 hour 54 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 2 hours 13 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 2 hours 30 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 2 hours 31 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 2 hours 32 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 10 hours 57 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 22 hours 34 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 10 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE

News